Adding new MRI features to the current diagnostic criteria for cerebral amyloid angiopathy (CAA) improves diagnostic accuracy, according to researchers in Boston, USA.
“The Boston criteria are used worldwide for in vivo diagnosis of CAA”, said Dr Andreas Charidimou of the Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts, USA.
Based on recent advances in CAA research, Dr Charimidou and colleagues developed an updated version of the Boston criteria (version 2.0 [v2.0]) and tested its ability to accurately diagnose CAA.